# Eosinophilic Asthma FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/eosinophilic-asthma

> 2 upcoming FDA catalysts in eosinophilic Asthma: KT-621 (KYMR) on December 2027 (primary completion); KT-621 (KYMR) on Dec 2027 to Mar 2028 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 21, 2026 | [Fasenra (benralizumab) primary completion](https://sec-api.dev/pdufa/benralizumab) | AZN | Eosinophilic Asthma | completed | "NCT06750289 (Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-21 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06750289)) |
| Sep to Dec 2026 | [Fasenra (benralizumab) topline data readout](https://sec-api.dev/pdufa/benralizumab) | AZN | Eosinophilic Asthma | scheduled | "NCT06750289 (Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-21 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06750289)) |
| December 2027 | [KT-621 primary completion](https://sec-api.dev/pdufa/kt-621) | KYMR | Eosinophilic Asthma | scheduled | "NCT07323654 (A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Kymera Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07323654)) |
| Dec 2027 to Mar 2028 | [KT-621 topline data readout](https://sec-api.dev/pdufa/kt-621) | KYMR | Eosinophilic Asthma | scheduled | "NCT07323654 (A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Kymera Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07323654)) |

## Drugs

- [Fasenra (benralizumab)](https://sec-api.dev/pdufa/benralizumab) (AZN)
- [KT-621](https://sec-api.dev/pdufa/kt-621) (KYMR)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/eosinophilic-asthma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Eosinophilic Asthma FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/eosinophilic-asthma

```bibtex
@misc{secapidev_indications_eosinophilic_asthma_20261116,
  title        = {Eosinophilic Asthma FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/eosinophilic-asthma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_eosinophilic_asthma_20261116","title":"Eosinophilic Asthma FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/eosinophilic-asthma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
